SATHI, G.;GUJRATI, V. R.;SHARMA, M.;NATH, C.;BHARGAVA, K. P.;SHANKER, K., ARCH. PHARM., 1983, 316, N 9, 767-772
作者:SATHI, G.、GUJRATI, V. R.、SHARMA, M.、NATH, C.、BHARGAVA, K. P.、SHANKER, K.
DOI:——
日期:——
New Quinolines as Potential CNS Agents
作者:Garima Sathi、Vibha R. Gujrati、Manju Sharma、Chandishwar Nath、Krishna P. Bhargava、Kirpa Shanker
DOI:10.1002/ardp.19833160908
日期:——
aryl‐1‐(4‐aminophenyl)piperazines and substituted piperidines with substituted 4‐chloroquinolines. The compounds were screened for their monoamine oxidase (MAO) inhibitory activities (in vitro) and various CNS activities (in vivo). Some compounds showed promising MAO inhibitory and antidepressant activities. The compounds did not produce acute neurological deficits and have low toxicity. Compound 1b is the
化合物1a-1l和2a-2m是通过各种芳基-1-(4-氨基苯基)哌嗪和取代哌啶与取代4-氯喹啉缩合合成的。筛选化合物的单胺氧化酶 (MAO) 抑制活性(体外)和各种 CNS 活性(体内)。一些化合物显示出有希望的 MAO 抑制和抗抑郁活性。这些化合物不会产生急性神经功能缺损并且具有低毒性。化合物 1b 是该系列中最活跃的成员。讨论了结构-活性关系。